The levels of cancer cell-derived EVs (CD326+/CD31+ and CD133+/CD31+) and TF+ cancer cell-derived EVs (CD326+142+/CD31+ and CD133+CD142+/CD31+) were higher in patients with cancer-related stroke than in patients with cancer-unrelated stroke (P<0.05 in all cases) (Fig 2). Here, TF is linked to stroke disorder.